ReviewClinical medicine insights. Reproductive health2014
Management of Vaginal Atrophy: Implications from the REVIVE Survey.
Review in Clinical medicine insights. Reproductive health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 78 citations in OpenAlex.
- Effect of zinc-containing pessaries on menopausal genitourinary syndrome, a double-blind randomised trial.BMC women's health · 2025Trial
- Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.JAMA internal medicine · 2018Trial
- Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.Menopause (New York, N.Y.) · 2017Trial
- The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.Menopause (New York, N.Y.) · 2017Trial
- Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis.Breast (Edinburgh, Scotland) · 2026Article
- Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- User acceptability profiles of vaginal treatments among women with genitourinary syndrome of menopause.PloS one · 2025Article
- Comparison of topical estrogen and platelet-rich plasma injections in the treatment of postmenopausal vaginal atrophy.Frontiers in medicine · 2025Article
- Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.International journal of women's health · 2024Review
- Fractional COJournal of clinical medicine · 2023Article
- Examining the Health-Related Needs of Females during Menopause: A Systematic Review Study.Journal of menopausal medicine · 2023Review
- Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship.Journal of clinical medicine · 2022Review
- An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy.Medical devices (Auckland, N.Z.) · 2021Article
- Economic Evaluation of SenshioApplied health economics and health policy · 2021Article
- Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.Drugs & aging · 2019Review
- Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women.Oman medical journal · 2017Article
- Evaluation of Symptoms and Prevention of Cancer in Menopause: The Value of Vulvar Exam.Translational medicine @ UniSa · 2016Article
- Predictors of impact of vaginal symptoms in postmenopausal women.Menopause (New York, N.Y.) · 2016Article
- Menopause and Sexuality.Endocrinology and metabolism clinics of North America · 2015Review
- What do portuguese women prefer regarding vaginal products? Results from a cross-sectional web-based survey.Pharmaceutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.